Physician profile
Kanika Monga
NPI 1982081915
$9,847.90
in general payments reported to CMS, 2019-2025
24 companies · $699 in 2025
The $699 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $68.77 · 2021: $292 · 2022: $1,198 · 2023: $1,019 · 2024: $6,570 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,680 · Food and Beverage: $2,764 · Travel and Lodging: $1,692 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,680.00 |
| Food and Beverage | $2,763.70 |
| Travel and Lodging | $1,691.66 |
| Education | $152.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $5,690.79 | 2020-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,340.75 | 2020-2025 | |
| Janssen Biotech, INC. | $1,197.39 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $360.55 | 2021-2025 | Tavneos, Otezla, Enbrel |
| Glaxosmithkline, LLC. | $273.31 | 2020-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $153.43 | 2021-2024 | Saphnelo |
| Fresenius Kabi USA, LLC | $147.65 | 2024-2025 | Idacio, Stimufend, Tyenne |
| Aurinia Pharma U.S., INC. | $106.92 | 2022-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $100.63 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.82 | 2022-2024 | Ofev |
| Pfizer INC. | $67.44 | 2022 | |
| Novo Nordisk INC | $50.26 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $39.90 | 2024 | Arcalyst |
| Abbott Laboratories | $32.98 | 2021 | |
| Grifols USA, LLC | $25.10 | 2024 | Xembify |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedrion Biopharma, INC. | $24.90 | 2024 | Koate, Kedrab, Gammaked |
| Takeda Pharmaceuticals U.S.A., INC. | $24.32 | 2024 | Cuvitru |
| Amarin Pharma, INC. | $23.76 | 2021 | |
| Hospira, INC. | $23.66 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $22.29 | 2021 | |
| Neurocrine Biosciences, INC. | $20.77 | 2021 | |
| Biocryst US Sales Co., LLC | $15.86 | 2024 | Orladeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.26 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanika Monga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.